Campaign targets Abercrombie "spraying"
This article was originally published in The Rose Sheet
Executive Summary
"Parents, teenagers, health-care professionals, faith organizations, environmental health and justice groups" representing 1.5 million people in total sign onto Campaign for Safe Cosmetics letter to Mike Jeffries, CEO of apparel and lifestyle brand Abercrombie & Fitch, asking company to discontinue its practice of spraying fragrance via air sprayers in its stores, which poses potential health risks to workers and shoppers in the more than 300 Abercrombie stores nationwide, group says. Its concerns are based on data showing "a significant percentage of the population reports adverse effects to fragrance products" and movement from U.S. Centers for Disease Control, other government offices and universities to implement fragrance-free policies. Citing Campaign's "Not So Sexy" report released in May, the alliance takes a leery view on Abercrombie's flagship scent Fierce, which it claims contains 11 "hidden" chemicals not listed on labeling, eight sensitizing chemicals associated with allergic reactions and diethyl phthalate, linked to reproductive toxicity in infants and adult males. Over the longer term, group urges the retailer to remove "hazardous chemicals" from its colognes and personal-care products. In addition to the letter, the Campaign has launched "a social media blitz" on Twitter and Facebook "demanding that A&F stop spraying.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.